Phase 4 N=53 Randomized Triple-blind Treatment

Intraoperative Sublingual Sufentanil for Acute Pain in the Ambulatory Surgery Center

Pain · Pain, Acute · Anesthesia

Bottom Line

View on ClinicalTrials.gov: NCT04387136 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2022

Primary outcome: Primary: Initial Numeric Rating Scale (NRS) Pain Score Upon Arrival — 4; 4 score on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Sublingual Sufentanil (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Minnesota
Primary completion: Feb 2021

Outcome Measures

Outcome	Result	p-value
PRIMARY Initial Numeric Rating Scale (NRS) Pain Score Upon Arrival	4; 4	—
SECONDARY Opioid Use in Recovery Room	7.5; 15.0	—
SECONDARY OBAS Score	1.0; 3.0	—

Summary

The purpose of this study is to determine if a single dose of sublingual sufentanil given 15-30 minutes prior to wake up is efficacious at reducing recovery room time.

Eligibility Criteria

Inclusion Criteria

Adult patients undergoing outpatient ambulatory surgery undergoing general anesthesia for orthopedic surgery

Exclusion Criteria

non-english speaking patients
patients who have allergy or intolerance to the study drugs or derivatives

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04387136). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.